Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 6, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 10, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-455719
Filed / recorded
Nov 10, 2026, 10:09 PM UTC
Added to OQRO
Nov 10, 2026, 10:10 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Aardvark Therapeutics, Inc.
Issuer CIK
1774857
Ticker
AARD
Reporting person
Manasi Jaiman
Relationship
Officer
Officer title
Chief Medical Officer
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Nov 6, 2026
Transaction code
A
Shares / units
70,549
Acquired / disposed
Acquired (A)
Shares owned after
70,549
Ownership form
Direct
Amendment
No
Footnotes from the filing
If this option is exercised prior to the end of the Retention Period (as defined in footnote (3)), the exercise price per share for such exercise shall be $13.48, the original exercise price per share, and not the New Exercise Price (as defined in footnote (3)) reflected in Column 2.
On August 14, 2026, the stockholders of the Issuer approved a proposal to reprice certain eligible outstanding stock options, including the stock options with exercise prices of $13.48, $11.29 and $4.24 listed in Table II (the "Repriced Options"). In accordance with this approval, on November 6, 2026, the exercise price of each Repriced Option was reduced to $1.26 (the "New Exercise Price"); provided that, for the New Exercise Price to apply, the Reporting Person must remain in Continuous Service (as defined in the applicable equity plan governing such option) with the Issuer from November 6, 2026 until the earlier of (i) November 6, 2027 and (ii) a Change in Control (as defined in the applicable equity plan governing such option) during the Reporting Person's Continuous Service with the Issuer (upon which such option shall accelerate in full) (such period, the "Retention Period").
(Continued from footnote 3) Following the repricing, each Repriced Option retains its respective original vesting schedule and expiration date.
1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.